{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:24:05Z","timestamp":1770747845076,"version":"3.49.0"},"reference-count":111,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,3,5]],"date-time":"2004-03-05T00:00:00Z","timestamp":1078444800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Despite the significant health impact of gout, there is no consensus on management standards. To guide physician practice, we sought to develop quality of care indicators for gout management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature review of gout therapy was performed using the Medline database. Two abstractors independently reviewed each of the articles for relevance and satisfaction of minimal inclusion criteria. Based on the review of the literature, 11 preliminary quality indicators were developed and then reviewed and refined by an initial feasibility panel of community and academic rheumatologists. A twelfth indicator was added at the request of the first panel. Using a modification of the RAND\/University of California at Los Angeles appropriateness method (bridging teleconference and white\u2010board Internet technology were added), a second expert panel rated each of the proposed indicators for validity using a 9\u2010point scale, in which ratings of 1\u20133, 4\u20136, and 7\u20139 were considered \u201cinvalid,\u201d \u201cindeterminate,\u201d and \u201chighly valid,\u201d respectively. Indicators were considered valid if the median panel rating was \u22657 and there was no evidence of panel disagreement (defined to occur when 2 of 6 panelists provided a validity rating of 1\u20133 and 2 panelists provided a validity rating of 7\u20139).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten of the 12 draft indicators were rated to be valid by our second expert panel. Validated indicators pertained to 1) the use of urate\u2010lowering medications in chronic gout, 2) the use of antiinflammatory drugs, and 3) counseling on lifestyle modifications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using a combination of evidence and expert opinion, 10 indicators for quality of gout care were developed. These indicators represent an important initial step in quality improvement initiatives for gout care.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.20102","type":"journal-article","created":{"date-parts":[[2004,3,10]],"date-time":"2004-03-10T08:00:43Z","timestamp":1078905643000},"page":"937-943","source":"Crossref","is-referenced-by-count":119,"title":["Quality of care indicators for gout management"],"prefix":"10.1002","volume":"50","author":[{"given":"Ted R.","family":"Mikuls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine H.","family":"MacLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Patino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroan J.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren B.","family":"Bilker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Saag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.1999.tb00139.x"},{"key":"e_1_2_6_3_2","first-page":"143","article-title":"A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed","volume":"23","author":"Evans TI","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","first-page":"346","article-title":"A survey of allopurinol dosage prescribing","volume":"108","author":"McClintock AD","year":"1995","journal-title":"N Z Med J"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-8_Part_2-200110161-00003"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806253382607"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300012022"},{"key":"e_1_2_6_8_2","first-page":"59","volume-title":"US Agency for Health Care Policy and Research Office of the Forum for Quality and Effectiveness in Health Care clinical practice guideline development: methodology perspectives","author":"Brook R","year":"1994"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530080048040"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612193352506"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-8_Part_2-200110161-00010"},{"issue":"8","key":"e_1_2_6_12_2","first-page":"694","article-title":"Quality indicators for the management of heart failure in vulnerable elders","volume":"135","author":"Fonarow GC","journal-title":"Ann Intern Med 200"},{"issue":"8","key":"e_1_2_6_13_2","first-page":"668","article-title":"Quality indicators for dementia in vulnerable community\u2010dwelling and hospitalized elders","volume":"135","author":"Chow TW","journal-title":"Ann Intern Med 200"},{"issue":"8","key":"e_1_2_6_14_2","first-page":"722","article-title":"Quality indicators for the management of osteoporosis in vulnerable elders","volume":"135","author":"Grossman JM","journal-title":"Ann Intern Med 200"},{"issue":"8","key":"e_1_2_6_15_2","first-page":"744","article-title":"Quality indicators for prevention and management of pressure ulcers in vulnerable elders","volume":"135","author":"Bates\u2010Jensen BM","journal-title":"Ann Intern Med 200"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-8_Part_2-200110161-00015"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1987.tb01232.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780170517"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-1433-3_28"},{"key":"e_1_2_6_20_2","first-page":"79","article-title":"Sequential studies of renal function in gout","volume":"3","author":"Gibson T","year":"1979","journal-title":"Eur J Rheumatol Inflam"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-9140-5_42"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.1.59"},{"key":"e_1_2_6_23_2","first-page":"1246","article-title":"Intermittent control of hyperuricemia in the treatment of gout","volume":"16","author":"Bull P","year":"1989","journal-title":"J Rheumatol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/ard.25.Suppl_6.623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"Scott JT","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_25_2","first-page":"498","article-title":"Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients: therapeutic equivalence to allopurinol","volume":"23","author":"Walter\u2010Sack I","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/10.3.247"},{"key":"e_1_2_6_27_2","first-page":"41","article-title":"Coronary angiography and revascularization: defining procedural indications through formal group processes","volume":"10","author":"Naylor CD","year":"1994","journal-title":"Can J Cardiol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1997.02170480015003"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199408000-00001"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7001.376"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/hs0901.94620"},{"key":"e_1_2_6_32_2","first-page":"495","article-title":"Systemic toxicity associated with intravenous administration of colchicine: guidelines for use","volume":"15","author":"Wallace S","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(68)90008-9"},{"key":"e_1_2_6_35_2","first-page":"263","article-title":"Studies of allopurinol in patients with impaired renal function","volume":"122","author":"Elion G","year":"1980","journal-title":"Biol Med"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6486.1969"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1977.tb03375.x"},{"key":"e_1_2_6_38_2","first-page":"143","article-title":"Allopurinol hypersensitivity vasculitis and liver damage","volume":"126","author":"Boyer T","year":"1977","journal-title":"West J Med"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(79)70031-4"},{"key":"e_1_2_6_40_2","first-page":"297","article-title":"Allopurinol hypersensitivity syndrome: effects and treatment","volume":"105","author":"Lindsey S","year":"1978","journal-title":"VA Med"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.1971.03180310037007","article-title":"Severe hypersensitivity reactions associated with allopurinol","volume":"216","author":"Mills R","year":"1971","journal-title":"JAMA"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.40.3.245"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290111"},{"key":"e_1_2_6_44_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity: association with thiazide and prior renal compromise","volume":"134","author":"Young J","year":"1974","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1990.tb00195.x"},{"key":"e_1_2_6_46_2","first-page":"96","article-title":"Increased danger of bone marrow damage in simultaneous azathioprine\u2010allopurinol therapy","volume":"19","author":"Zazgornik J","year":"1981","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_6_47_2","first-page":"126","article-title":"Effects of xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia, and gout","volume":"76","author":"Rundles R","year":"1963","journal-title":"Trans Assoc Am Physicians"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199710150-00027"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)02031-4"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780190209"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1961.03040110035008"},{"key":"e_1_2_6_52_2","first-page":"400","article-title":"Allopurinol in the treatment of gout secondary to hyperuricemia","volume":"16","author":"Rundles R","year":"1966","journal-title":"Bull Rheum Dis"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780080455"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.29.5.461"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-62-4-639"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.25.Suppl_6.627"},{"key":"e_1_2_6_57_2","first-page":"306","article-title":"Control of hyperuricemia with hydroxypyrazolopyrimidine, a purine analogue which inhibits uric acid synthesis","volume":"6","author":"Wymgaarden J","year":"1963","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(64)90131-7"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.26.2.136"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780080456"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780080457"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.39.5.529-a"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90076-7"},{"key":"e_1_2_6_64_2","first-page":"21","article-title":"Observations and effects of educational consults on allopurinol prescribing","volume":"45","author":"Devlin J","year":"1992","journal-title":"Can J Hosp Pharm"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-9140-5_46"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780180735"},{"key":"e_1_2_6_67_2","first-page":"305","article-title":"Pharmacokinetic and clinical studies of a new uricosuric agent: benzbromarone","volume":"3","author":"Yu T","year":"1976","journal-title":"J Rheumatol"},{"key":"e_1_2_6_68_2","first-page":"372","article-title":"The clinical and metabolic effects of benemid in patients with gout","volume":"64","author":"Talbott J","year":"1951","journal-title":"Trans Assoc Am Physicians"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-1433-3_40"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.34.3.256"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.231.11.1143"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341203"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.23.6.439"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.33.4.304"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-9140-5_47"},{"key":"e_1_2_6_76_2","first-page":"663","article-title":"The failure of uricosuric drugs to reduce the attack rate in primary nontophaceous gout","volume":"12","author":"Gaines LM","year":"1969","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(57)91541-6"},{"key":"e_1_2_6_78_2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.25.Suppl_6.634","article-title":"Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone","volume":"25","author":"Kuzell W","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03401.x"},{"key":"e_1_2_6_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315424"},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6637.1641-a"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(72)92271-4"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(54)90337-X"},{"key":"e_1_2_6_84_2","first-page":"410","article-title":"Safety and effectiveness of colchicine by intravenous administration in the treatment of gout","volume":"9","author":"Davis J","year":"1969","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1959.63010120002013a"},{"key":"e_1_2_6_86_2","first-page":"163","article-title":"Clinoril in acute gout","volume":"8","author":"Calabro J","year":"1974","journal-title":"Acta Rheum Port"},{"key":"e_1_2_6_87_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5547.272"},{"key":"e_1_2_6_88_2","first-page":"560","article-title":"Indomethacin in the treatment of acute gout","volume":"194","author":"Boardman P","year":"1965","journal-title":"Practitioner"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.239.1.34"},{"key":"e_1_2_6_90_2","first-page":"365","article-title":"Efficacy, tolerance and safety of piroxicam in the treatment of acute gout","volume":"1","author":"Tausch G","year":"1978","journal-title":"Eur J Rheumatol Inflam"},{"key":"e_1_2_6_91_2","first-page":"346","article-title":"Safety and efficacy of piroxicam in the treatment of acute gout","volume":"1","author":"Widmark P","year":"1978","journal-title":"Eur J Rheumatol Inflam"},{"key":"e_1_2_6_92_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/030006057900700605","article-title":"Piroxicam in the treatment of acute gout: a multicentre open study in general practice","volume":"7","author":"Murphy J","year":"1979","journal-title":"J Intern Med Res"},{"key":"e_1_2_6_93_2","first-page":"176","article-title":"Ibuprofen (brufen) treatment of acute gouty arthritis","volume":"18","author":"Karachalios G","year":"1981","journal-title":"Clin Trial J"},{"key":"e_1_2_6_94_2","first-page":"63","article-title":"Treatment of gouty arthritis with piroxicam","volume":"3","author":"Karachalios G","year":"1985","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_95_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1952.02930250011004"},{"key":"e_1_2_6_96_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009747309097100"},{"key":"e_1_2_6_97_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1742-1241.1985.tb07791.x","article-title":"Clinical experience with isoxicam in patients with acute gout","volume":"39","author":"Fletcher MA","year":"1985","journal-title":"Br J Clin Pract"},{"key":"e_1_2_6_98_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058000800504"},{"key":"e_1_2_6_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1975.tb01465.x"},{"key":"e_1_2_6_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780190516"},{"key":"e_1_2_6_101_2","first-page":"1422","article-title":"Ketoprofen vs. indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study","volume":"15","author":"Altman R","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_6_102_2","first-page":"641","article-title":"Meclofenamate sodium in the treatment of acute gout: results of a double\u2010blind study","volume":"33","author":"Eberl R","year":"1993","journal-title":"Arzneimittel\u2010Forschung"},{"key":"e_1_2_6_103_2","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricemia","volume":"37","author":"Fraser R","year":"1987","journal-title":"J Royal Col Gen Pract"},{"key":"e_1_2_6_104_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009747809095668"},{"key":"e_1_2_6_105_2","first-page":"351","article-title":"Comparison of indomethacin and phenylbutazone in acute gout","volume":"32","author":"Smyth C","year":"1973","journal-title":"Practitioner"},{"key":"e_1_2_6_106_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.36.1.80"},{"key":"e_1_2_6_107_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780220420"},{"key":"e_1_2_6_108_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007998009109465"},{"key":"e_1_2_6_109_2","first-page":"111","article-title":"Piroxicam in the treatment of acute gout: high dose versus low dose","volume":"68","author":"Tumrasvin T","year":"1985","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_6_110_2","first-page":"275","article-title":"Comparison of phenylbutazone and flufenamic acid in treatment of acute gout","volume":"10","author":"Douglas G","year":"1970","journal-title":"Ann Phys Med"},{"key":"e_1_2_6_111_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05110.x"},{"key":"e_1_2_6_112_2","first-page":"264","article-title":"Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout","volume":"18","author":"Wallace S","year":"1991","journal-title":"J Rheumatol"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.20102","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.20102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T21:13:53Z","timestamp":1700774033000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.20102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":111,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1002\/art.20102"],"URL":"https:\/\/doi.org\/10.1002\/art.20102","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}